摘要
目的:研究富含亮氨酸的α-2-糖蛋白1(LRG1)和糖链抗原125(CA125)在上皮性卵巢癌患者血清中的表达,探讨联合检测LRG1、CA125对上皮性卵巢癌的诊断价值。方法:采用酶联免疫吸附法(ELISA法)和化学发光法检测40例上皮性卵巢癌、20例卵巢良性肿瘤患者及17例健康妇女血清中LRG1和CA125水平,分析其与临床病理特征的关系,比较单独检测LRG1、CA125与两者联合检测诊断上皮性卵巢癌的敏感度和特异度。结果:卵巢癌组血清中的LRG1、CA125水平明显高于卵巢良性肿瘤组及健康对照组,差异均有统计学意义(P<0.05),卵巢良性肿瘤组和正常对照组则无明显差异(P>0.05)。卵巢癌组患者血清中的LRG1水平与临床病理分期、淋巴结转移呈正相关(P<0.05)。联合检测LRG1、CA125受试者工作特征曲线下面积显著大于单独检测CA125(P<0.05)。结论:联合检测血清LRG1及CA125水平可提高上皮性卵巢癌的早期诊断率,LRG1可能作为上皮性卵巢癌早期诊断潜在的生物学标记。
Objective：To evaluate the clinical significance of serum leucine-rich alpha- 2-glycoprotein（ LRG1 ） and carbohydrate antigen 125 （ CA125 ） in patients with epithelial ovari- an cancer. Methods：The serum levels of LRG1 and CA125 were determined by ELISA and chemiluminescence assay in 17 cases of healthy women,20 cases of benign ovarian cystadeno- ma, and 40 cases of epithelial ovarian cancer. Results： The serum levels of LRG1 and CA125 in cases of epithelial ovarian cancer were significant higher than those in case of benign ovarian cystadenoma and healthy women （P 〈 0. 05 ）. The difference between the cases of healthy women and benign ovarian cystadenoma was not significant （P 〉 O. 05 ）. The serum level of LRG1 in cases of ovarian epithelial cancer was direct correlated with the clinicopathologie stage, lymph node metastasis. The areas under the receiver operating characteristic （ROC） curve （AUC） for combined detection of serum LRG1 and CA125 was significant higher than the detection of CA125 lonely. Conclusion： The diagnostic sensitivity is significantly improved by combined detection of serum LRG1 and CA125 than detection of them lonely, LRG1 may be a potential candidate biomarker for early detection of ovarian cancer.
出处
《现代妇产科进展》
CSCD
2013年第2期111-114,共4页
Progress in Obstetrics and Gynecology
基金
甘肃省青年科技基金计划(No:099RJYA010)
陇原青年创新人才扶持计划(甘卫人函<2008>93号)
